ライフサイエンスコーパス: diagnostic assay

1 mass spectrometry (MALDI-TOF MS) and a fucK diagnostic assay.

2 TP) as an illustrative example of a low cost diagnostic assay.

3 r PCR enzyme immunoassay (PCR-EIA) used as a diagnostic assay.

4 ng that this system could be the basis for a diagnostic assay.

5 r PCR based on IS2404 has shown promise as a diagnostic assay.

6 e and used to develop a species-specific PCR diagnostic assay.

7 ively small and generally only used a single diagnostic assay.

8 were tested for vaginitis using a molecular diagnostic assay.

9 ity for a suite of microfluidic CRISPR-based diagnostic assays.

10 orated with microfluidic or laboratory scale diagnostic assays.

11 ations in rapid, minimally invasive clinical diagnostic assays.

12 llow-up studies will yield highly innovative diagnostic assays.

13 the potential to improve the performance of diagnostic assays.

14 apid and reliable confirmation of disease by diagnostic assays.

15 or the development of novel therapeutics and diagnostic assays.

16 indly tested with the gold standard and smpB diagnostic assays.

17 ogical surface functionalization for bedside diagnostic assays.

18 e samples that were RV positive in multiplex diagnostic assays.

19 cs and biomarker discovery, and for clinical diagnostic assays.

20 ints but are not widely used as reporters in diagnostic assays.

21 rain collections to enable assessment of new diagnostic assays.

22 ng assays) as well as for portable low-power diagnostic assays.

23 s (sibling 3-5) were tested using a range of diagnostic assays.

24 tention as a potential platform for low-cost diagnostic assays.

25 this gene has served as the best target for diagnostic assays.

26 ghput screens for pharmacological agents and diagnostic assays.

27 o facilitate development of high sensitivity diagnostic assays.

28 d costs are significant limiting factors for diagnostic assays.

29 is important when interpreting C. difficile diagnostic assays.

30 ificant improvement over currently available diagnostic assays.

31 f microarray hybridization data and clinical diagnostic assays.

32 ive alternative to blood for many biomedical diagnostic assays.

33 t in identifying both therapeutics and rapid diagnostic assays.

34 e fingerprints for microarray-based pathogen diagnostic assays.

35 peutic applications, as well as steady state diagnostic assays.

36 ted as potential probes for microarray-based diagnostic assays.

37 g an amenable method for automatic RAM-based diagnostic assays.

38 ints for design of microarray-based pathogen diagnostic assays.

39 st in using this technology as the basis for diagnostic assays.

40 seem to be particularly difficult for fungal diagnostic assays.

41 the usefulness of comparative evaluations of diagnostic assays.

42 sily produced alternative antigen for use in diagnostic assays.

43 potential wide use in clinical research and diagnostic assays.

44 de application to a large number of clinical diagnostic assays.

45 as potential candidates for vaccines and/or diagnostic assays.

46 allow the development of novel therapies and diagnostic assays.

47 extremely low concentrations of analytes in diagnostic assays.

48 idates and for developing improved serologic diagnostic assays.

49 manufacture of calibrators and controls for diagnostic assays.

50 rains, circumvent the limitations of current diagnostic assays.

51 to those determined by VNT and LPBE standard diagnostic assays.

52 , available therapeutics, and sequence-based diagnostic assays.

53 timize the use of more invasive or expensive diagnostic assays.

54 rable to that of the currently used clinical diagnostic assays.

55 er-probe sets used in four common SARS-CoV-2 diagnostic assays.

56 r analytical devices and other point-of-care diagnostic assays.

57 combinant affinity proteins for use in rapid diagnostic assays.

58 ild transmission, and the development of new diagnostic assays.

59 nucleic acid biomarkers for multiparametric diagnostic assays.

60 by Sanger sequencing or commercial molecular diagnostic assays.

61 n be used to develop new dengue vaccines and diagnostic assays.

62 erefore serve as a positive control in Ebola diagnostic assays.

63 system for either genetic analysis or other diagnostic assays.

64 t of technology for the rapid development of diagnostic assays.

65 Using the novel smpB diagnostic assay, 100% concordance was observed with the

66 ay for M. leprae, were validated as clinical diagnostic assays according to Clinical Laboratory Impro

67 CR for M. leprae, were validated as clinical diagnostic assays according to Clinical Laboratory Impro

68 nificant increase in the number of molecular diagnostic assays, achievement of amplification directly

69 s of detection of rotavirus were compared by diagnostic assay and specimen type.

70 utine clinical tests is essential to improve diagnostic assays and advance toward personalized tuberc

71 s disease makes the development of sensitive diagnostic assays and antemortem sampling techniques cru

72 s disease makes the development of sensitive diagnostic assays and antemortem sampling techniques cru

73 able the development of genetic barcodes for diagnostic assays and clinical studies.

74 sential for designing broadly cross-reactive diagnostic assays and dissecting the immune response to

75 d for the development of clinically relevant diagnostic assays and evaluation of therapeutic agents a

76 misdiagnosed because of low availability of diagnostic assays and expertise and classified as bullou

77 or investigating pathogenesis and developing diagnostic assays and for vaccine development.

78 d source of organisms for the development of diagnostic assays and forming a basis for future studies

79 duction of cultivation-independent molecular diagnostic assays and highly multiplexed serologic analy

80 bility of new improved strategies to support diagnostic assays and methods for drug treatment monitor

81 channel is important for the development of diagnostic assays and microreactors and for performing f

82 generated structures as bioactive probes for diagnostic assays and molecular transport junctions.

83 ied new cancer pathways and led to molecular diagnostic assays and molecular-targeted chemotherapies

84 ded for use in clinical research to evaluate diagnostic assays and not for individual patient diagnos

85 rotein levels were quantified using standard diagnostic assays and nuclear magnetic resonance (NMR) s

86 uidelines have been published to standardise diagnostic assays and once implemented may yield more ac

87 c shear would lead to the development of new diagnostic assays and pave the way to clinical approache

88 utbreak strain and the probes and primers of diagnostic assays and the antigenic sites of the experim

89 results emphasize the limitations of current diagnostic assays and the potential for single-cell mapp

90 HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions.

91 Consequently, diagnostic assays and therapy for ITP lack specificity.

92 pB, and development of methylated OmpB-based diagnostic assays and vaccine candidates.

93 recombination and for the design of various diagnostic assays and vaccine constructs.

94 can help in selecting optimal candidates for diagnostic assays and vaccine development.

95 d be considered in the future development of diagnostic assays and vaccine preparations.

96 tivity and specificity expected of PCR-based diagnostic assays and will contribute new insight regard

97 pid prototyping of hand-held, visually read, diagnostic assays (and other microfluidic systems) based

98 rovides insight into the pathogenic process, diagnostic assays, and potential therapeutic agents.

99 e, the potential benefits and limitations of diagnostic assays, and the likelihood that agents in dev

100 el of P. malariae to study parasite biology, diagnostic assays, and treatment.

101 MP Diagnostics assay, in 29.5% by the Axiom Diagnostics assay, and in 18% by the Mikrogen assay.

102 solations in research laboratories, clinical diagnostics assays, and cell therapy manufacturing.

103 riations of MSPs and in their utilities in a diagnostic assay are discussed.

104 Mainstream diagnostic assays are challenged by their intrinsic dive

105 rgence of new viral variants and ensure that diagnostic assays are contemporary and fully optimized.

106 ultiplexed, sensitive, and on-chip molecular diagnostic assays are essential in both clinical and res

107 Paper-based diagnostic assays are gaining increasing popularity for

108 Recently developed filarial molecular diagnostic assays are highly sensitive and specific but

109 nform clinical action, but current molecular diagnostic assays are restricted in resolution and throu

110 operation and safety, as well as Ebola virus diagnostic assays, are described and discussed; in addit

111 volves development of fluorescent cell-based diagnostic assay as a new approach in high-throughput sc

112 ave heightened the need available commercial diagnostic assays as well as standardized methods for de

113 ves are components of vaccine candidates and diagnostic assays, as well as tools for research into th

114 t of a novel, inexpensive, and user-friendly diagnostic assay based on a reverse transcription-insula

115 ingle-tube, dual channel pentaplex molecular diagnostic assay based on Multiplex Probe Amplification

116 the development of the TickPath Layerplex, a diagnostic assay based on qPCR methodology that was adap

117 e a serious obstacle in the development of a diagnostic assay based on TaqMan PCR; however, the quant

118 The feasibility of developing molecular diagnostic assays based on the accelerated photobleachin

119 However, the development of point-of-care diagnostic assays based on this binding has been challen

120 , above reported sensitivity limits of novel diagnostic assays being considered for simplified HCV tr

121 Epidemiological and clinical diagnostic assays benefit from accurate detection of del

122 the development of the BTA stat and BTA TRAK diagnostic assays, both of which make use of two factor

123 w WGS can be exploited to evaluate molecular diagnostic assays by using publicly available data, onli

124 , and reaction chambers such that the entire diagnostic assay can be automatically executed on a sing

125 This single-tube diagnostic assay can be performed in 2 h or less and can

126 -consuming; recent advances, translated into diagnostic assays, can improve testing and facilitate ty

127 Current commercial diagnostic assays cannot differentiate EV-D68 from other

128 or a highly sensitive and specific molecular diagnostic assay capable of detecting the natural geneti

129 A sensitive, low-cost diagnostic assay capable of rapidly evaluating the effec

130 hts the need for rapid, sensitive SARS-CoV-2 diagnostic assays capable of high-throughput operation t

131 Thus, a phosphoprotein-based diagnostic assay combined with Cdk5-targeted therapy is

132 However, current diagnostic assays commonly require long assay time, soph

133 Molecular diagnostic assays detected Borrelia miyamotoi in the per

134 ase Control and Prevention real-time RT-qPCR diagnostic assays detected Ituri and Makona Ebola virus

135 , there are a number of challenges to fungal diagnostic assay development that have been difficult hu

136 lications for both C. pneumoniae vaccine and diagnostic assay development.

137 Diagnostic assays distinguishing HHV-6B reactivation fro

138 With impressive advances in in vitro diagnostic assays during the last decade, ELISAs have be

139 The current functional diagnostic assays employ inhibition of activated C1s; ho

140 While all microbial diagnostic assays face challenges before they are FDA ap

141 protocol developed here can be applied as a diagnostic assay, facilitating monitoring of Vgsc CN in

142 Our results suggest that development of a diagnostic assay for acute typhoid fever focused on dete

143 onal connectivity magnetic resonance imaging diagnostic assay for autism.

144 te and speed up an important and widely used diagnostic assay for bloodstream infections.

145 A rapid diagnostic assay for CaPV would be useful for disease su

146 The CRAG LFA is an accurate diagnostic assay for CSF and should be considered for po

147 roviding the basis of an improved commercial diagnostic assay for EIAV infection of horses.

148 Use of sequencing-based genotyping as a diagnostic assay for human immunodeficiency virus (HIV)

149 We have developed a new diagnostic assay for limb girdle muscular dystrophy 2B a

150 demand for a simple broad-spectrum molecular diagnostic assay for pathogenic bacteria.

151 Specific IFN-gamma detection is a novel diagnostic assay for previous C. burnetii infection and

152 PSA structures could form a basis for a new diagnostic assay for prostate cancer.

153 Development of a valid diagnostic assay for quick detection (in less than an ho

154 Proof of concept for a novel diagnostic assay for rubella virus (RUB) based on RUB re

155 rred to here as OSOM) is a new point-of-care diagnostic assay for T. vaginalis that uses an immunochr

156 This is the first diagnostic assay for the detection of aMPV-C-specific an

157 e of an RNA aptamer for the development of a diagnostic assay for the detection of chemical residues

158 a fully automated sample-to-answer molecular diagnostic assay for the detection of influenza A, influ

159 iable, sensitive, and specific point-of-need diagnostic assay for the diagnosis of DENV in clinics an

160 usly reported, as well as a highly sensitive diagnostic assay for the ultratrace quantitation of a ph

161 tocol yields a rapid, sensitive, and precise diagnostic assay for the ultratrace quantitation of a th

162 In an effort to develop a rapid diagnostic assay for tularemia, we investigated the use

163 There is a need for a reliable, simple diagnostic assay for typhoid fever.

164 This work would open the door to real-time diagnostic assays for a wide range of diseases, but also

165 y been used to improve the design of several diagnostic assays for bacterial pathogens.

166 rovide alternative approaches to develop POC diagnostic assays for broad applications in medicine, th

167 and have implications for developing robust diagnostic assays for cancer patient stratification.

168 robiota fingerprints to develop (i) specific diagnostic assays for cetacean population conservation a

169 in enhancing the sensitivity of blood-based diagnostic assays for CWD and other TSEs.

170 r more sensitive, fast and/or less expensive diagnostic assays for dengue.

171 hich has allowed the development of standard diagnostic assays for detection of serum autoantibodies-

172 We also tested diagnostic assays for detection of the Ituri Ebola virus

173 Rapid, reliable, and easy-to-use diagnostic assays for detection of Zaire ebolavirus (ZEB

174 velopment of simple and affordable molecular diagnostic assays for infectious diseases, especially in

175 ustry for evaluation or development of novel diagnostic assays for LD, to continue to improve upon cu

176 However, diagnostic assays for M. genitalium have been limited in

177 enotyping approaches for rapid detection and diagnostic assays for molecular epidemiological and clin

178 Available diagnostic assays for Mycobacterium avium subsp. paratub

179 onsiderations when developing field-portable diagnostic assays for near-patient environments.

180 Currently, diagnostic assays for nucleic acids must be individually

181 Rapid diagnostic assays for PfCRT mutations are already employ

182 s many of the features required to implement diagnostic assays for RNA viruses in settings that lack

183 esigned an array of cpn60-targeted molecular diagnostic assays for SbGP/MPV phytoplasma.

184 ities and specificities of several different diagnostic assays for Streptococcus pneumoniae were asse

185 ew types necessitate regular updating of the diagnostic assays for the accurate and comprehensive det

186 es-specific rRNA sequences have been used in diagnostic assays for the detection and identification o

187 Rapid and sensitive diagnostic assays for the detection of tuberculous mycob

188 oglobin (HbA1c) is one of the most important diagnostic assays for the long-term mark of glycaemic co

189 form in vitro photodynamic therapy (PDT) and diagnostic assays for treatment assessment on a single p

190 Novel diagnostic assays for tuberculosis have conventionally b

191 ress has been made in the development of new diagnostic assays for tuberculosis in recent years.

192 a simple, low-cost, alternative to existing diagnostic assays for tuberculosis screening in HIV-infe

193 Current serological diagnostic assays for typhoid fever are based on detecti

194 viral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard geno

195 mplification strategy aimed toward threshold diagnostic assays for use in resource-limited settings i

196 analysis may serve as a parameter for future diagnostic assays for women with breast implants to dist

197 and cancer, and for development of companion diagnostics assays for individualized medicine.

198 ood cells offer the opportunity to develop a diagnostic assay from blood samples.

199 ulted in the need for sensitive and specific diagnostic assays, fully validated for the detection of

200 e of the following four SARS-CoV-2 molecular diagnostic assays granted emergency use authorization by

201 ry data indicate that, when PCR-based fungal diagnostic assays guide antifungal therapy, they may low

202 The lack of commercially available diagnostic assays has limited widespread routine testing

203 This shift in our understanding of the diagnostic assays has re-invigorated the examination of

204 previous associated lack of rapid, sensitive diagnostic assays, has impaired recognition of AdV infec

205 Recently, diagnostic assays have been developed to detect platelet

206 Sensitive diagnostic assays have increased the detection of viruse

207 em promising for possible inclusion in a new diagnostic assay: hemolysin E (HlyE), cytolethal distend

208 d probes for use in probe-based nucleic acid diagnostic assays (i.e., PCR-ELISA).

209 ormed with a commercially available in vitro diagnostic assay (ImmuKnow; Viracor-IBT Laboratories, Le

210 esent technologies in on-site or at home POC diagnostic assays implemented in paper-based microfluidi

211 Results of diagnostic assays implicated the household transmission

212 nts involved in a sandwich immunoassay based diagnostic assay in electrode-enabled microwell plates i

213 quantum dots may enable more simple, robust diagnostic assays in the future.

214 These vectors may also be useful in diagnostic assays in which infectious VEEV is undesirabl

215 viduals, HEV IgG was found in 4.5% by the MP Diagnostics assay, in 29.5% by the Axiom Diagnostics ass

216 ce the utility of sdAb incorporated into any diagnostic assay, including those for high consequence p

217 s advance has enabled the development of new diagnostic assays, including in situ hybridization, PCR

218 infection was confirmed by a combination of diagnostic assays, including molecular tests, immunohist

219 flow to obtain high-quality control data for diagnostic assays, including the use of ITEM-THREE as a

220 rmeasures (vaccines, therapeutic agents, and diagnostic assays), infrastructure, and human resources.

221 e variation for the performance of molecular diagnostic assays is not well studied.

222 cs-based approach to the development of LAMP diagnostic assays is the first of its kind for fungi and

223 This diagnostic assay may also have veterinary applications d

224 Comprehensive diagnostic assays must therefore identify all possible D

225 econdition for the successful development of diagnostic assays of cerebrospinal fluid (CSF) biomarker

226 mise as vaccines and are being developed for diagnostic assays of other viruses.

227 Point-of-care diagnostic assays often involve multistep reactions, req

228 Traditional diagnostic assays often lack sensitivity and can be diff

229 Both antibodies are used in Abbott diagnostic assays on AxSYM, IMx, and Architect platforms

230 ial IgA anti beta2GPI antibodies (abeta2GPI) diagnostic assays on specimens from individuals suspecte

231 nsufficient for successful implementation in diagnostic assays or as therapeutic agents.

232 This study therefore reports an advanced diagnostic assay performed on an integrated microfluidic

233 piratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic assays play a central role in diagnosis and h

234 Rapid, accurate POC diagnostic assays play a crucial role in developing coun

235 Rapid, sensitive and specific diagnostic assays play an indispensable role in determin

236 To demonstrate the clinical utility of the diagnostic assay presented, a panel of lower RTI samples

237 The RT-PCR and antigen-capture diagnostic assays proved very effective for detecting eb

238 Medical diagnostic assays provide exquisite sensitivity and prec

239 me highly promising for future point-of-care diagnostic assays, pushing sensitivity towards single-mo

240 portant new opportunities for development of diagnostic assays, sequential bioprocessing, and lab ass

241 ches to the delivery of sensitive yet rugged diagnostic assays specific for emerging viruses, to hast

242 uss the clinical range, diagnostic criteria, diagnostic assay systems, and treatment options for this

243 econd-generation and new rapid point-of-care diagnostic assays take advantage of recent genetic and m

244 In this study, a novel real-time PCR diagnostic assay targeting the smpB gene was designed to

245 n effort to develop a new class of molecular diagnostic assay that can rapidly assess drug resistance

246 ibe a multiplex droplet digital PCR clinical diagnostic assay that concurrently distinguishes between

247 We have fabricated a point of care rapid diagnostic assay that employs fluorescent, micellar sili

248 Developing any diagnostic assay that receives United States Food and Dr

249 We describe a diagnostic assay that simultaneously monitors for reject

250 The development of a rapid H. influenzae diagnostic assay that would allow for the implementation

251 l flow immunoassays (LFIs) are point-of-care diagnostic assays that are designed for single use outsi

252 Point-of-care diagnostic assays that are rapid, easy-to-use, and low-c

253 There is a need for culture-free diagnostic assays that can be carried out rapidly, and m

254 Diagnostic assays that can be used in conjunction with r

255 ults of this study will aid in the design of diagnostic assays that can detect prion disease across t

256 enerated in the study can be used to improve diagnostic assays that differentiate HSV-1 from HSV-2 in

257 as a substrate for ultrasensitive and robust diagnostic assays that may be suitable for clinical test

258 is challenging, and the definitive serologic diagnostic assay, the microscopic agglutination test, is

259 id output for which there is already a known diagnostic assay, then that single assay could be easily

260 sodB target may offer an improved molecular diagnostic assay to detect Ehrlichia spp.

261 hese signatures can be used as the basis for diagnostic assays to detect and genotype microbes in bot

262 is-a-vis protective immunity, the ability of diagnostic assays to detect novel variants, and the poss

263 This finding provides a basis for developing diagnostic assays to differentiate species of borrelia t

264 Rapid diagnostic assays to distinguish more common infectious

265 al need for noninvasive, easy to administer, diagnostic assays to help assess whether a prostate biop

266 Noninvasive diagnostic assays to improve current late and nonspecifi

267 ies the critical need for accurate and rapid diagnostic assays to prompt clinical and public health i

268 reagents in the preparation of vaccines and diagnostic assays to protect against and diagnose Lyme d

269 f heritable variation in resistance and that diagnostic assays to test the importance of other resist

270 he different M. bovis doses, suggesting that diagnostic assays (tuberculin skin test and IFN-gamma te

271 sed devices can be an essential component of diagnostic assays used at the point-of-care.

272 rove the reliability of a group of important diagnostic assays used in the evaluation of systemic rhe

273 The portfolio of diagnostic assays used in the GEMS study can be broadly

274 therapies, confirm the effectiveness of the diagnostic assays used in the region, and establish a pa

275 Current diagnostic assays used to identify CA-MRSA strains are b

276 atments can be linked to the approval of new diagnostic assays used to measure efficacy or to predict

277 Here, we describe a multi-marker diagnostic assay using 5 markers (ARPC2, FN1, RGS1, SPP1

278 The development of diagnostic assays using highly targeted specific aptamer

279 t human pathogenic Fusarium in a single-well diagnostic assay, using flow cytometry and fluorescent m

280 Two rapid diagnostic assays, utilizing two different Luminex flow

281 successfully used to fabricate voltammetric diagnostic assay via immobilization onto chitosan exfoli

282 Unlike previous CRISPR diagnostic assays, we also use ITP for automated purific

283 Using total RNA sequencing and targeted diagnostic assays, we discovered an outbreak of parvovir

284 sition, the amplification conditions for the diagnostic assay were not affected.

285 Diagnostic assays were performed in 4,169 at-risk person

286 gent need for a simple and rapid serological diagnostic assay which can differentiate between antibod

287 tor can be used to standardize aspergillosis diagnostic assays which detect and/or quantify nucleic a

288 the development and evaluation of molecular diagnostic assays, which continue to play an important r

289 Currently available diagnostic assays, which include polymerase chain reacti

290 Rapid, vaccine strain-specific diagnostic assays will more efficiently distinguish VARI

291 Hence, a diagnostic assay with easy visualization of the amplifie

292 ers can be used as biorecognition element in diagnostic assays with commercial application for mycoto

293 he approach described is applicable to other diagnostic assays with imperfect detection.

294 for the further development of point-of-care diagnostic assays with low-cost, robust reagents and sim

295 ics may lead to development of user-friendly diagnostic assays with simple readouts.

296 moniae should be confirmed using one or more diagnostic assays with well-documented high (e.g., > or

297 e internal control clone to be loaded into a diagnostic assay without negatively affecting it.

298 d employed directly for downstream molecular diagnostic assays without any further processing.

299 ) facilitating the availability of molecular diagnostic assays without the more rigorous examination

300 tbreak of any magnitude, a field-based rapid diagnostic assay would allow proper patient transport an